The PTO’s Patent Trial and Appeal Board will evaluate the validity of three Genentech patents covering its blockbuster breast cancer treatment Herceptin, following petitions for inter partes review filed by…

Intellipharmaceutics artificially inflated its stock prices during the NDA process for its oxycodone product Rexista, a new class-action lawsuit claims. Source: Drug Industry Daily

A third-party evaluator should be used to assess the expanded communications program proposed in the next generation of the FDA’s biosimilar user fees, according to BIO. Source: Drug Industry Daily

As part of the Trump administration’s deregulatory push, the FDA has withdrawn nine regulations proposed for the pharmaceutical industry, some in the works for years. Source: Drug Industry Daily

A White House commission on opioid abuse, established in March by executive order, delivered its initial set of recommendations to President Trump, urging him to declare an immediate, national state…